




RealRate

PHARMACEUTICAL 2021

Acura Pharmaceuticals INC
Rank 373 of 394



The relative strengths and weaknesses of Acura Pharmaceuticals INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Acura Pharmaceuticals INC compared to the market average is the variable Other Revenues, increasing the Economic Capital Ratio by 16% points. The greatest weakness of Acura Pharmaceuticals INC is the variable Stockholders Equity, reducing the Economic Capital Ratio by 241% points.

The company's Economic Capital Ratio, given in the ranking table, is 69%, being 188% points below the market average of 256%.

Input Variable	Value in 1000 USD
Assets, Current	1,179
Cost of Goods Sold	0
Intangible Assets	73
Liabilities, Current	7,522
Liabilities, Non-Current	0
Other Assets	0
Other Compr. Net Income	0
Other Expenses	450
Other Liabilities	105
Other Net Income	0
Other Revenues	3,570
Property and Equipment	484
Research and Development	1,781
Selling, General and Administrative Expense	2,547

Output Variable	Value in 1000 USD
Assets	1,736
Liabilities	7,627
Expenses	4,778
Revenues	3,570
Stockholders Equity	-5,891
Net Income	-1,208
Comprehensive Net Income	-1,208
BaseVar	8,856
ECR before LimitedLiability	-300%
Economic Capital Ratio	69%